The NHS is unambiguous: there is currently no cure for atopic eczema, and the treatments that exist help manage the symptoms (NHS, Atopic eczema). Accurate, and it says little about what happens to any one person over years. The large cohorts that have followed people for decades give answers that look incompatible. The disagreement is not about biology. It is about what counts as remission, and that distinction says more about your prospects than the word cure does.
Two large studies, two different answers
Margolis and colleagues followed 7,157 children in the Pediatric Eczema Elective Registry for 22,550 person-years. At every age from 2 to 26 years, more than 80% of participants had symptoms of atopic dermatitis and/or were using medication to treat it, and it was not until age 20 that half the cohort had recorded even one lifetime six-month symptom and treatment free period (Margolis et al, 2014).
A pooled analysis reads the other way round. Kim and colleagues combined 45 studies covering 110,651 subjects and 434,992 patient-years across 15 countries. In that analysis, 80% of childhood atopic dermatitis did not persist by 8 years, and less than 5% persisted by 20 years after diagnosis. Children who developed it by age 2 had less persistent disease (Kim et al, 2016).
Both figures are real, and they measure different things. Margolis counted medication use as active disease, so settled skin on a maintenance treatment still counted as eczema, and remission required six unbroken months free of both symptoms and treatment. The pooled analysis is looser, and its authors say so: persistence came out higher in studies using patient or carer assessment than where a clinician assessed the skin, and some included studies did not capture recurrences later in life (Kim et al, 2016). One person can sit in the remission group of one dataset and the persistent group of the other.
Remission moves in both directions
Abuabara and colleagues applied latent class analysis to two British birth cohorts followed into midlife: 15,939 people in the 1958 National Child Development Study and 14,966 in the 1970 British Cohort Study. Most participants, 88 to 91%, had a rare or absent probability of reporting eczema. Beyond them sat three smaller groups: a decreasing pattern at around 4%, an increasing pattern at 2 to 6%, and a persistently high pattern at 2 to 3% (Abuabara et al, 2021).
The increasing group undercuts the usual story. Activity does not only fade with age. In a minority it climbs, and that subtype only becomes visible once the observation window extends past childhood.
The same team's earlier analysis found annual period prevalence between 5% and 15%, and that among adults with active eczema in a given year, only 38% reported symptoms beginning in childhood (Abuabara et al, 2019). Adult eczema is mostly not childhood eczema that never left.
Why the underlying tendency stays
Remission is not the tendency disappearing, because part of that tendency is fixed. In the 1958 cohort, at least one FLG-null mutation was carried by 21% of people with childhood-onset disease, 13% of those with adult-onset disease, and 10% of those with no history of eczema (Abuabara et al, 2019). Filaggrin is a structural protein. A loss-of-function variant in the gene that makes it is not something a treatment edits.
The lipid half of the defect is not inherited the same way, but it is structural rather than episodic too. What is missing from the mortar between the cells is covered in the skin barrier article. Either way the conditions that let a flare start are present when there is no flare, which is why guidance is written around control rather than removal.
What holding a remission involves
Two jobs, not one.
The first is knowing what sets your skin off, which is a recording problem more than a knowledge problem. Exposures overlap and severity drifts, and neither is reconstructed accurately from memory weeks later. A structured food diary is the dietary version, scored daily.
The second is not stopping when nothing is happening. Schmitt and colleagues pooled eight vehicle-controlled trials of proactive treatment: an anti-inflammatory applied to previously affected skin on a fixed low-frequency schedule after a flare settles, not only when a new one starts. Twice-weekly fluticasone propionate gave a relative risk of at least one flare of 0.46 (95% CI 0.38 to 0.55) against vehicle, and tacrolimus ointment 0.78 (95% CI 0.60 to 1.00) (Schmitt et al, 2011). The schedule belongs to a prescriber, but the principle holds: the quiet period is when flare prevention happens. NHS emollient advice follows the same logic, to carry on moisturising even once eczema improves.
Judging any of it takes weeks rather than days, because what shows now was set in motion earlier in the skin's renewal cycle.
What the newer systemic drugs change
Dupilumab, tralokinumab, lebrikizumab and the oral JAK inhibitors act on the signalling that drives the inflammation, and for moderate to severe disease that topical treatment has not controlled they change the picture. Who they suit is covered in the biologics article.
What they do not alter is the barrier defect or the genotype beneath it. They change how much disease a person carries while taking them: control held in place by an ongoing intervention, not removal of the tendency.
The honest answer
Cure means the tendency is gone, and nothing on offer does that.
Remission means long stretches with nothing active to treat. Those are common, they are what the protocol walkthrough is organised around, and the cohort data add two qualifications: they can be interrupted, and in a minority activity rises with age instead of falling.
That is a more answerable frame. The question stops being whether this will go away and becomes what keeps yours quiet, and for how long. If the answer is not for long, that is information about the management, and a treatment that is not working is its own question.
References
- NHS. Atopic eczema. https://www.nhs.uk/conditions/atopic-eczema/
- Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatology, 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC4352328/
- Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2016, 75:681-687. https://pmc.ncbi.nlm.nih.gov/articles/PMC5216177/
- Abuabara K, Ye M, Margolis DJ, et al. Patterns of atopic eczema disease activity from birth through midlife in 2 British birth cohorts. JAMA Dermatology, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8411362/
- Abuabara K, Ye M, McCulloch CE, et al. Clinical onset of atopic eczema: results from 2 nationally representative British birth cohorts followed through midlife. Journal of Allergy and Clinical Immunology, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6721832/
- Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology, 2011. https://doi.org/10.1111/j.1365-2133.2010.10030.x